VK2735 Maintenance Dosing Results: Weekly, Every-Other-Week, and Monthly Compared
VK2735 maintenance dosing preserved a company-reported 90% of prior weight loss with combined every-other-week regimens and 85% with combined monthly regimens over 12 weeks. Here is how those topline results compare with continued weekly treatment, placebo, and current semaglutide and tirzepatide buying options.
Short Answer: What the VK2735 Maintenance Dosing Results Show
VK2735 maintenance dosing retained 90% of prior weight loss across the combined every-other-week groups and 85% across the combined monthly groups during a 12-week maintenance phase. Participants switched to placebo retained 61%. A small exploratory group that continued 17.5 mg weekly reached 21.7% mean total weight loss at week 33.
These are September 2026 company-reported topline findings from VK2735-102, not a peer-reviewed maintenance publication. VK2735 is a dual GIP and GLP-1 receptor agonist, the same receptor pair targeted by tirzepatide, but results cannot be transferred between molecules. Readers comparing an available dual-agonist option can start with the tirzepatide guide and live tirzepatide prices.
How the 33-Week Study Was Designed
VK2735-102 was described as randomized, double-blind, and placebo-controlled. The reported analysis covered approximately 180 otherwise healthy adults with obesity and BMI of at least 30 kg/m².
Participants completed 21 weeks of once-weekly induction, followed by 12 weeks of weekly, every-other-week, monthly, or placebo maintenance. Final weekly induction amounts were 15, 17.5, 20, or 22.5 mg after two-week escalation steps. Those are study-arm facts, not a personal schedule.
The current registry is NCT07838740, other study ID VK2735-102, and lists Phase 1 with estimated enrollment of 270 because the broader protocol includes additional oral-regimen work. The 12-week maintenance window measures short-term retention, not multi-year durability.
Induction Results Before Maintenance
At week 21, mean weight loss was:
- 16.3% with 15 mg weekly
- 17.8% with 17.5 mg weekly
- 18.7% with 20 mg weekly
- 17.1% with 22.5 mg weekly
- 0.1% with placebo
All active comparisons were reported at p<0.0001. Mean baseline weights were 108.4 kg, 95.9 kg, 101.9 kg, and 103.0 kg across the four active groups. Their sample sizes were 14, 118, 15, and 14. The placebo group had n=15 and a 100.0 kg mean baseline weight.
Across the combined VK2735 groups, 98% lost at least 5%, 90% lost at least 10%, 65% lost at least 15%, and 32% lost at least 20%. Placebo values were 13%, 0%, 0%, and 0%.
The peer-reviewed VENTURE Phase 2 trial provides earlier but separate context. Its 13-week efficacy counts included 174 participants, with 140 active and 34 placebo. Mean active weight reduction ranged from 9.1% at 2.5 mg to 14.7% at 15 mg, versus 1.7% with placebo. Among active participants, 130 of 140, or 93%, lost at least 5%, compared with 4 of 34, or 12%, on placebo.
VENTURE is indexed as PMID 41508550 and DOI 10.1002/oby.70106. Do not merge its peer-reviewed evidence level with the newer maintenance topline.
Weekly vs Every-Other-Week vs Monthly: The Data
| Transition | Maintenance amount | n | Week-21 loss retained at week 33 | p vs placebo |
|---|---|---|---|---|
| VK2735 to placebo | Placebo | 27 | 61% | Not reported |
| Combined every other week | Mixed | 37 | 90% | <0.0001 |
| 17.5 mg weekly to every other week | 5 mg | 12 | 83% | 0.004 |
| 15 mg weekly to every other week | 7.5 mg | 13 | 90% | <0.0001 |
| 17.5 mg weekly to every other week | 10 mg | 12 | 97% | <0.0001 |
| Combined monthly | Mixed | 65 | 85% | <0.0001 |
The combined result is the cleanest topline comparison: 90% retention every other week and 85% monthly, versus 61% after transition to placebo. The component groups are small, so the apparent spread from 83% to 97% should not be read as a settled dose-ranking system.
The continued-weekly group is also different from the reduced-frequency rows. It was an exploratory control rather than a randomized head-to-head maintenance-percentage comparison against every other regimen.
Monthly Components and Weekly Control
| Transition | Monthly amount | n | Week-21 loss retained at week 33 | p vs placebo |
|---|---|---|---|---|
| 17.5 mg weekly to monthly | 10 mg | 16 | 82% | 0.0016 |
| 17.5 mg weekly to monthly | 15 mg | 14 | 84% | 0.0012 |
| 17.5 mg weekly to monthly | 17.5 mg | 11 | 90% | 0.0002 |
| 20 mg weekly to monthly | 20 mg | 14 | 86% | 0.0005 |
| 22.5 mg weekly to monthly | 22.5 mg | 10 | 85% | 0.0024 |
The company excluded one participant in the highest monthly cohort because that person’s maintenance effect was more than 2.5 standard deviations from the cohort mean. Including that participant would have produced 99% retention for that cohort. That does not change the combined monthly result to 99%, but it materially changes one small subgroup and belongs in the interpretation.
The exploratory continued-weekly group kept 17.5 mg weekly, had n=13, and reached 21.7% mean total weight loss at week 33. That result suggests continued weekly treatment could support additional loss, while the reduced-frequency groups were designed to test retention. It does not establish a randomized universal winner across all schedules.
Tolerability During the 12-Week Maintenance Phase
The combined every-other-week safety group had n=37. Any treatment-emergent adverse event was reported by 38%. Mild nausea occurred in 5%, vomiting in 3%, diarrhea in 5%, and constipation in 0%. One participant, or 3%, discontinued because of an adverse event.
The combined monthly safety group had n=66. Any treatment-emergent adverse event occurred in 49%. Mild nausea was reported by 4.5%, vomiting by 8%, diarrhea by 5%, and constipation by 3%. One participant, or 2%, discontinued because of an adverse event.
The placebo group had n=27. Any treatment-emergent adverse event occurred in 52%, with nausea in 0%, vomiting in 7%, diarrhea in 4%, and constipation in 4%. No placebo participant discontinued early.
Viking said gastrointestinal-event rates during maintenance were not meaningfully different from placebo. The exact counts still matter because percentages can move sharply in groups this small.
During the 21-week induction phase, one participant, or 1%, discontinued VK2735 because of an adverse event. The company described the common gastrointestinal events as mild and declining over time. These tolerability findings remain part of the same company-reported topline dataset, not a peer-reviewed maintenance paper.
What Buyers Can Compare Today
PeptidePub does not have a VK2735 price page or tracked vendor offer. There is no honest VK2735 price, affiliate route, or vendor recommendation to invent from this study.
For current GLP-1 and GIP research comparisons, use the tirzepatide guide, tirzepatide price comparison, semaglutide guide, and semaglutide price comparison. Neither compound should be assumed to reproduce VK2735 results.
In PeptidePub’s October 20, 2026 snapshot, the best tested-vendor tirzepatide value was $1.50 per mg at NextGen Peptides for 60 mg after code `peptidepub`. The cheapest 5 mg option was $9 per mg, so the 60 mg unit price was about 83% lower. Prices and inventory can change.
For semaglutide, the best value was $1.85 per mg at RetaOne Labs for 20 mg after code `peptidepub`. The best-tested listing was Glacier Aminos at $2.92 per mg with 7 of 7 testing checks. Again, check the live page before checkout rather than treating a dated snapshot as today’s inventory.
Compare Evidence Before Checkout
A low per-milligram number is useful only when the product evidence matches what is being sold. Check exact identity, current-lot match, quantitative net content, purity, named laboratory, sterility, endotoxin, heavy-metal, and contaminant evidence through the vendor directory and PeptidePub methodology.
Then check current deals and discount codes. Compare the delivered price for the exact vial size and lot rather than assuming a larger vial or stronger vendor-wide score automatically verifies the item in your cart.
Readers looking for clinician-led current GLP-1 care can also compare providers. MEDVi’s live review lists a $179 first-month entry price for compounded injections and $299 per refill as of October 23, 2026. If that route fits the comparison, use the verified MEDVi link.
The useful buying takeaway is not that tirzepatide, semaglutide, or a provider program equals VK2735. It is that available options can be compared on current price, exact-vial evidence, testing depth, and support while VK2735 maintenance results continue to mature.
FAQ
What is VK2735?
VK2735 is Viking Therapeutics’ dual GIP and GLP-1 receptor agonist. It is being studied in subcutaneous and oral forms for weight management and metabolic disorders.
Did monthly VK2735 maintain all the weight loss?
No. The combined monthly groups retained 85% on average over 12 weeks. Component groups ranged from 82% to 90%. One excluded outlier would have changed the highest monthly cohort result to 99%, not the combined monthly result.
Was every-other-week dosing better than monthly dosing?
The combined figures favored every other week, with 90% retention versus 85% monthly. That five-point difference is interesting, but the study was small, component regimens used different amounts, and the results come from a company topline release. They do not establish one universal best maintenance schedule.
For context on why maintenance matters after GLP-1 treatment, see what happens when you stop a GLP-1. Readers comparing the two established receptor approaches can also review semaglutide versus tirzepatide.
How did reduced-frequency dosing compare with stopping?
The group transitioned to placebo retained 61% of prior loss over 12 weeks. Combined every-other-week groups retained 90%, and combined monthly groups retained 85% over the same period. That is the clearest maintenance signal in the release.
Can buyers purchase the exact trial product through PeptidePub?
No tracked VK2735 offer or price page exists. Compare current semaglutide and tirzepatide choices on their verified PeptidePub price and vendor pages instead of treating another product as VK2735.
Does the study settle long-term maintenance?
No. The maintenance phase lasted 12 weeks after 21 weeks of induction. It shows short-term retention through week 33, not multi-year durability. The component groups were also small, and the 33-week findings have not yet been published as a peer-reviewed maintenance paper.
Maintenance is also about what is being preserved. The guide to GLP-1 weight loss and lean mass explains why scale weight alone does not capture the full body-composition picture.
Bottom Line
The strongest VK2735 result is the maintenance signal. Combined every-other-week dosing retained 90% of prior weight loss and combined monthly dosing retained 85% over 12 weeks, compared with 61% after transition to placebo. A small exploratory group continuing 17.5 mg weekly reached 21.7% mean total weight loss at week 33.
The important limits are equally specific: a short maintenance window, small regimen groups, company-reported topline status, and one consequential outlier exclusion in the highest monthly cohort. Including that participant would have moved that cohort to 99% retention, but it would not make the combined monthly result 99%.
The earlier 13-week VENTURE efficacy trial is peer reviewed. The newer 33-week maintenance findings are not yet a peer-reviewed publication. Keep those evidence levels separate.
For decisions available now, compare tirzepatide prices, semaglutide prices, vendor testing, the testing methodology, provider options, and current deals. That is more useful than guessing from a headline percentage or assuming one molecule reproduces another molecule’s trial.
Sources
Follow @PeptidePub on X for daily peptide price drops.
Get peptide price-drop alerts
Set a target price and we'll email you when a trusted, third-party-tested vendor drops below it. No spam, unsubscribe anytime.